Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.45 |
| ▸ | F7 | P08709 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4630972 | 0.84 | EGFR (0.41) | SMN1; SMN2MAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL22394632 | 0.81 | MAPT (0.41) | SMN1; SMN2MAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL30808537 | 0.81 | MAPT (0.41) | SMN1; SMN2MAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL18044447 | 0.81 | ATM (0.55) | SMN1; SMN2MAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2579065 | 0.79 | LMNA (0.53) | SMN1; SMN2MAPTRAB9ANPC1HPGD | |
| SCHEMBL18151909 | 0.78 | CA1 (0.44) | MAPTRAB9ANPC1LMNAATM | |
| SCHEMBL8481716 | 0.76 | LMNA (0.43) | MAPTRAB9AMRGPRX4RXRALMNA | |
| SCHEMBL2188210 | 0.75 | SMPD1 (0.76) | SMN1; SMN2MAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2063068 | 0.75 | SMN1; SMN2 (0.73) | SMN1; SMN2MAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL18080982 | 0.73 | LMNA (0.54) | SMN1; SMN2MAPTCYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3067351-B1 | COMPOUND HAVING HIGHER INHIBITION OF PROTEIN KINASE G ACTIVITY AND PREPARATION METHOD THEREFOR | JENKEM TECH CO LTD TIANJIN (CN) | 2019-02-06 | — | — | EP | disclosed |
| US-9925171-B2 | Compound having higher inhibitory activity on protein kinase G and preparation method thereof | Jenkem Technology Co., Ltd., (Tianjin) (CN) | 2018-03-27 | — | — | US | disclosed |
| US-9925171-B2 | Compound having higher inhibitory activity on protein kinase G and preparation method thereof | Jenkem Technology Co., Ltd., (Tianjin) (CN) | 2018-03-27 | — | — | US | disclosed |
| US-9925171-B2 | Compound having higher inhibitory activity on protein kinase G and preparation method thereof | Jenkem Technology Co., Ltd., (Tianjin) (CN) | 2018-03-27 | — | — | US | disclosed |
| US-20170119736-A1 | COMPOUND HAVING HIGHER INHIBITORY ACTIVITY ON PROTEIN KINASE G AND PREPARATION METHOD THEREOF | Jenkem Technology Co., Ltd., (Tianjin) (CN) | 2017-05-04 | — | — | US | disclosed |
| US-20170119736-A1 | COMPOUND HAVING HIGHER INHIBITORY ACTIVITY ON PROTEIN KINASE G AND PREPARATION METHOD THEREOF | Jenkem Technology Co., Ltd., (Tianjin) (CN) | 2017-05-04 | — | — | US | disclosed |
| US-20170119736-A1 | COMPOUND HAVING HIGHER INHIBITORY ACTIVITY ON PROTEIN KINASE G AND PREPARATION METHOD THEREOF | Jenkem Technology Co., Ltd., (Tianjin) (CN) | 2017-05-04 | — | — | US | disclosed |
| US-9567319-B2 | Compound having higher inhibitory activity on protein kinase G and preparation method thereof | JENKEM TECHNOLOGY CO. LTD., (TIANJIN) (CN) | 2017-02-14 | — | — | US | disclosed |
| US-9567319-B2 | Compound having higher inhibitory activity on protein kinase G and preparation method thereof | JENKEM TECHNOLOGY CO. LTD., (TIANJIN) (CN) | 2017-02-14 | — | — | US | disclosed |
| US-9567319-B2 | Compound having higher inhibitory activity on protein kinase G and preparation method thereof | JENKEM TECHNOLOGY CO. LTD., (TIANJIN) (CN) | 2017-02-14 | — | — | US | disclosed |
| US-20160304501-A1 | COMPOUND HAVING HIGHER INHIBITORY ACTIVITY ON PROTEIN KINASE G AND PREPARATION METHOD THEREOF | Jenkem Technology Co., Ltd., (Tianjin) (CN) | 2016-10-20 | — | — | US | disclosed |
| US-20160304501-A1 | COMPOUND HAVING HIGHER INHIBITORY ACTIVITY ON PROTEIN KINASE G AND PREPARATION METHOD THEREOF | Jenkem Technology Co., Ltd., (Tianjin) (CN) | 2016-10-20 | — | — | US | disclosed |
| US-20160304501-A1 | COMPOUND HAVING HIGHER INHIBITORY ACTIVITY ON PROTEIN KINASE G AND PREPARATION METHOD THEREOF | Jenkem Technology Co., Ltd., (Tianjin) (CN) | 2016-10-20 | — | — | US | disclosed |
| EP-3067351-A1 | COMPOUND HAVING HIGHER INHIBITION OF PROTEIN KINASE G ACTIVITY AND PREPARATION METHOD THEREFOR | Jenkem Technology Co. Ltd. (Tianjin) (CN) | 2016-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304501-A1 | COMPOUND HAVING HIGHER INHIBITORY ACTIVITY ON PROTEIN KINASE G AND PREPARATION METHOD THEREOF | PRKCG, PRKG2, PKN3 | SMN1; SMN2 3558/4885MAPT 4286/4885CYP1A2 1737/4885 |
| US-20170119736-A1 | COMPOUND HAVING HIGHER INHIBITORY ACTIVITY ON PROTEIN KINASE G AND PREPARATION METHOD THEREOF | PRKCG, PRKG2, PKN3 | SMN1; SMN2 3558/4885MAPT 4286/4885CYP1A2 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.